These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 30244652)

  • 1. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
    Lu J; Han B
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer.
    Chen K; Kang G; Zhao H; Zhang K; Zhang J; Yang F; Wang J
    Expert Rev Mol Diagn; 2019 May; 19(5):419-427. PubMed ID: 30905203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Biopsy in the Clinical Management of Cancers.
    Ho HY; Chung KK; Kan CM; Wong SC
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
    Guibert N; Pradines A; Favre G; Mazieres J
    Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies.
    Chang L; Li J; Zhang R
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188729. PubMed ID: 35436521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of liquid biopsies in gastrointestinal cancer.
    Wu C; Zhang J; Li H; Xu W; Zhang X
    Clin Biochem; 2020 Oct; 84():1-12. PubMed ID: 32540214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools.
    Garcia J; Kamps-Hughes N; Geiguer F; Couraud S; Sarver B; Payen L; Ionescu-Zanetti C
    Sci Rep; 2021 May; 11(1):10761. PubMed ID: 34031447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
    Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
    Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA: Measurement and Clinical Utility.
    Donaldson J; Park BH
    Annu Rev Med; 2018 Jan; 69():223-234. PubMed ID: 28846488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
    Zhang X; Ju S; Wang X; Cong H
    Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
    Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.
    Al-Obeidi E; Riess JW; Malapelle U; Rolfo C; Gandara DR
    Hematol Oncol Clin North Am; 2023 Jun; 37(3):475-487. PubMed ID: 37024388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future perspectives of liquid biopsies in genomics-driven oncology.
    Heitzer E; Haque IS; Roberts CES; Speicher MR
    Nat Rev Genet; 2019 Feb; 20(2):71-88. PubMed ID: 30410101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA for personalized lung cancer monitoring.
    Fiala C; Diamandis EP
    BMC Med; 2017 Aug; 15(1):157. PubMed ID: 28814291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
    Addanki S; Meas S; Sarli VN; Singh B; Lucci A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
    Krebs MG; Malapelle U; André F; Paz-Ares L; Schuler M; Thomas DM; Vainer G; Yoshino T; Rolfo C
    JAMA Oncol; 2022 Dec; 8(12):1830-1839. PubMed ID: 36264554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.